يعرض 121 - 140 نتائج من 2,317 نتيجة بحث عن '(( significant barrier biased ) OR ( significant ((ns decrease) OR (nn decrease)) ))', وقت الاستعلام: 0.48s تنقيح النتائج
  1. 121
  2. 122
  3. 123
  4. 124

    HFD decreases ITM and alters metabolic homeostasis. حسب Tong Yue (6033305)

    منشور في 2025
    "…Two-way ANOVA, n.s., not significant, ** p < 0.01). <b>(F)</b> Long-term memory (LTM) was significantly decreased in the HFD group. …"
  5. 125
  6. 126
  7. 127

    B2 decreases glycolytic intermediates in cells. حسب Craig Eyster (392633)

    منشور في 2025
    "…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …"
  8. 128

    Downregulation of DOM decreases the abundance of PER and TIM. حسب Zhenxing Liu (399809)

    منشور في 2019
    "…Error bars represent ± SEM; n.s., non significant,*<i>P</i> < 0.05,**p < 0.01, ***p < 0.001, one-way ANOVA. …"
  9. 129
  10. 130

    Depletion of ERp29 decreases cellular Proinsulin. حسب Jeffrey Viviano (8871581)

    منشور في 2020
    "…(D, E) Transiently transfected Min-6 cells were lysed and analyzed by ELISA. Proinsulin levels decreased when transfected with ERp29-targeting siRNA as compared to controls (D, p = 0.0309), but Insulin content did not significantly change (E, p = ns).…"
  11. 131
  12. 132

    Regenerating axons are increased by ATRA and decreased by clodronate. حسب Valeria De La Rosa-Reyes (6658613)

    منشور في 2021
    "…Numbers of animals are shown. Asterisks or “ns” above each column indicate the significance when compared to PBS control (row 1, gray), ATRA (row 2, green), or clodronate (row 3, red) with ANOVA and <i>post-hoc</i> Tukey tests. …"
  13. 133
  14. 134

    GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage حسب Wieslaw M. Kazmierski (1706686)

    منشور في 2020
    "…The discovery of GSK2818713 (<b>13</b>), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly improved genotype coverage relative to first-generation NS5A inhibitor daclatasvir (DCV), is detailed herein. …"
  15. 135
  16. 136
  17. 137
  18. 138

    Baseline characteristics. حسب Nattapat Nitinai (17896679)

    منشور في 2024
    الموضوعات:
  19. 139
  20. 140